Background We evaluated 18F-FDG PET/CT in small cell lung cancer (SCLC) staging and
assessed metabolic (SUVmax, MTV and TLG) and morphologic (CTvol) variables as …

… -body 18 F-FDG PET on staging and managing patients with small cell lung cancer (SCLC). …
Whole-body 18 F-FDG PET was performed for initial staging in 24 patients and for restaging …

… emission tomography (PET) parameters in patients with small cell lung cancer (SCLC).
However, studies are often small, and there is a considerable interstudy disagreement about …

… Lung cancer is the leading cause of cancer mortality in Western society and its … of lung
cancer are diagnosed each year in the USA [1]. About 20% of these tumours are small-cell lung …

… The high uptake of 18F-FDG in most lung cancers and the … evidence supporting the
role of 18F-FDG PET are discussed. … form of lung cancer is non–small cell lung cancer (NSCLC). …

… This study was performed to answer the question of whether fluorine-18 labelled 2-… ,
FDG-PET has potential for use as a simplified staging and re-staging tool for small cell lung cancer, …

… imaging with 18 F-FDG PET has an established role in the standard of care in presurgical
staging of patients with non–small cell lung cancer (NSCLC). The addition of 18 F-FDG PET to …

… 18 2-fluoro-2-deoxy-D-glucose ( 18 F-FDG) PET or PET/computed tomography (CT) in the
pretherapeutic staging of patients with small-cell lung cancer … LR− of 18 F-FDG PET or PET/CT …

Background The identification of surgical non-small cell lung cancer (NSCLC) patients with
poor prognosis is a priority in clinical oncology because of their high 5-year mortality. This …

… PET using 18 F-FDG is a promising technique to monitor … 18 F-FDG PET scans were
obtained on 2 groups of patients. First, 10 patients with advanced non–small cell lung cancer (…